Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Kymera Therapeutics, Inc. - Common Stock (NQ:KYMR)

20.86 -3.09 (-12.88%)
Streaming Delayed Price Updated: 11:18 AM EDT, Apr 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Kymera Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Kymera Therapeutics Provides Webcast Information for December 14 Investor Event
Company to Share Clinical Data from KT-474 Phase I Patient Cohort and Oncology Pipeline 
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Looking Into Kymera Therapeutics's Return On Capital Employed
Via Benzinga
Where Kymera Therapeutics Stands With Analysts
Analysts have provided the following ratings for Kymera Therapeutics (NASDAQ:KYMR) within the last quarter: 
Via Benzinga
5 Analysts Have This to Say About Kymera Therapeutics
Analysts have provided the following ratings for Kymera Therapeutics (NASDAQ:KYMR) within the last quarter: 
Via Benzinga
5 Analysts Have This to Say About Kymera Therapeutics
Kymera Therapeutics (NASDAQ:KYMR) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Recap: Kymera Therapeutics Q3 Earnings
Kymera Therapeutics (NASDAQ:KYMR) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
5 Analysts Have This to Say About Kymera Therapeutics
  Within the last quarter, Kymera Therapeutics (NASDAQ:KYMR) has observed the following analyst ratings: 
Via Benzinga
Analyst Ratings for Kymera Therapeutics
Kymera Therapeutics (NASDAQ:KYMR) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2022
Upgrades 
Via Benzinga
Kymera Therapeutics Announces Third Quarter 2022 Financial Results and Provides a Business Update
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics Appoints Biopharmaceutical Leader Victor Sandor, M.D.C.M., to Board of Directors
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics to Report Third Quarter 2022 Results on November 3
Company also presenting at upcoming investor conferences 
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics to Hold Investor Webcast on December 14 to Share Clinical Data from KT-474 Phase I Patient Cohort and Oncology Pipeline
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary
Via Benzinga
Kymera Gets Orphan Drug Status For Rare Blood Cancer Candidate
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Kymera Therapeutics’ (NASDAQ: KYMR) product candidate KT-333 for the treatment of Cutaneous T-cell Lymphoma (CTCL). 
Via Benzinga
Looking Into Kymera Therapeutics's Return On Capital Employed
Kymera Therapeutics (NASDAQ:KYMR) brought in sales totaling $11.51 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 9.74%, resulting in a loss of $40.26... 
Via Benzinga
Where Kymera Therapeutics Stands With Analysts
Over the past 3 months, 6 analysts have published their opinion on Kymera Therapeutics (NASDAQ:KYMR) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
Insiders Buying Ecolab, Kymera Therapeutics And This Consumer Cyclical Stock
Although US stocks closed mostly lower on Tuesday, there were a few notable insider trades. 
Via Benzinga
Kymera Therapeutics Stock Scores Rising Relative Price Strength
Kymera Therapeutics stock hit a key performance benchmark, with its Relative Strength Rating upgradedjulie mak to 94. 
Via Investor's Business Daily
Kymera Therapeutics: Q2 Earnings Insights
  Kymera Therapeutics (NASDAQ:KYMR) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2022
  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 15, 2022
  
Via Benzinga
Kymera Therapeutics Commences Initial-Stage Oncology Trials
Kymera Therapeutics, Inc. (NASDAQ: KYMR) has recently initiated dosing of patients in separate Phase 1 clinical trials evaluating its oncology drug candidates KT-333 and KT-413. 
Via Benzinga
The Daily Biotech Pulse: FDA Committee Backs Moderna Shot For 5-17 Years, 180 Life Sciences Stock Plunges, Pfizer's Posts Disappointing Paxlovid Data
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2022
Upgrades 
Via Benzinga
Why Kymera Therapeutics Stock Is Gaining Wednesday
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Kymera Therapeutics (NASDAQ: KYMR) lead drug candidate KT-333 for the treatment of patients with Peripheral T-cell... 
Via Benzinga
Fresh Del Monte Produce And 2 Other Stocks Insiders Are Buying
Although the Dow Jones dropped more than 200 points on Tuesday, there were a few notable insider trades. 
Via Benzinga
3 Biotech Stocks to Buy Before They Boom
It could be a “never-before, never-after opportunity” to buy into these biotech stocks that trade at very attractive valuations. 
Via InvestorPlace
Executives Buy Around $141M Of 4 Stocks
Although Dow Jones futures traded higher this morning on Tuesday, there were a few notable insider trades. 
Via Benzinga
81 Biggest Movers From Yesterday
Gainers Rail Vision Ltd. (NASDAQ: RVSN) shares climbed 62.4% to close at $2.16 on Wednesday after gaining around 5% on Tuesday. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.